Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials

BACKGROUND: In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibrosis (IPF) with nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent with slowing disease progression. However, nintedanib was not assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreuter, Michael, Wuyts, Wim A., Wijsenbeek, Marlies, Bajwah, Sabrina, Maher, Toby M., Stowasser, Susanne, Male, Natalia, Stansen, Wibke, Schoof, Nils, Orsatti, Leticia, Swigris, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990488/
https://www.ncbi.nlm.nih.gov/pubmed/32000772
http://dx.doi.org/10.1186/s12931-020-1298-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990488/
https://www.ncbi.nlm.nih.gov/pubmed/32000772
http://dx.doi.org/10.1186/s12931-020-1298-1

Ejemplares similares